Table 2.
Predictors of first-line PFS and OS in the study cohort. Univariable Cox models.
| Endpoint |
PFS |
OS |
||||
|---|---|---|---|---|---|---|
| Variable | Hazard ratio | 95% CI | p | Hazard ratio | 95% CI | p |
| Demographic variables | ||||||
| Age (per 5 years increase) | 0.95 | 0.83–1.09 | 0.496 | 1.02 | 0.88–1.17 | 0.826 |
| Female sex | 1.05 | 0.59–1.86 | 0.876 | 1.33 | 0.72–2.44 | 0.360 |
| ECOG ⩾1 point | 0.85 | 0.46–1.57 | 0.595 | 1.77 | 0.96–3.27 | 0.070 |
| Caucasian ethnicity | N/A | N/A | N/A | N/A | N/A | N/A |
| Cancer variables | ||||||
| Stage IV at time of tumor diagnosis | 1.96 | 0.90–4.26 | 0.089 | 1.82 | 0.78–4.29 | 0.168 |
| Liver metastasis | 1.16 | 0.52–2.57 | 0.720 | 1.42 | 0.60–3.33 | 0.421 |
| Lung metastasis | 1.44 | 0.86–2.41 | 0.164 | 0.98 | 0.56–1.72 | 0.947 |
| KRAS mutation | 0.87 | 0.51–1.50 | 0.628 | 1.34 | 0.75–2.41 | 0.326 |
| IHC variables | ||||||
| CD31 (microvessels/HPF, per doubling) | 0.52 | 0.29–0.92 | 0.024 | 1.21 | 0.70–2.10 | 0.491 |
| PTEN IHC positive | N/A | N/A | N/A | N/A | N/A | N/A |
| Any uPAR expression | 0.71 | 0.42–1.20 | 0.204 | 0.76 | 0.43–1.34 | 0.339 |
| NRP-1 expression (per 1-point increase) | 0.99 | 0.86–1.14 | 0.869 | 1.07 | 0.92–1.25 | 0.380 |
| αV-integrin expression (per 1-point increase) | 0.97 | 0.85–1.12 | 0.697 | 1.01 | 0.86–1.18 | 0.949 |
| CD98he positivity | 0.55 | 0.31–0.96 | 0.035 | 0.68 | 0.37–1.22 | 0.192 |
| Treatment variables | ||||||
| Randomization to Arm B | 0.66 | 0.40–1.09 | 0.102 | 1.29 | 0.75–2.22 | 0.360 |
ECOG, ; HPF, higher-power fields; IHC, ; OS, overall survival; PFS, progression-free survival; PTEN, phosphatase and tensin homolog; uPAR, urokinase receptor.